We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer/Oncology
-
2. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
3. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
4. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
5. Pediatric cancer testing
- Prof. Joshua Schiffman
- Neurology/Neuroscience
-
8. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
9. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
- Cardiovascular
-
10. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
- Respiratory Diseases
-
12. Predicting asthma exacerbations using machine learning models
- Dr. Nestor Molfino
- Immunology & Inflammation
-
13. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
14. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
- Infectious Diseases/Microbiology
-
15. Combating the HIV epidemic
- Prof. William Blattner
-
16. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
- Clinical Practice
-
18. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
-
19. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
20. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
21. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
22. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
Topics Covered
- Pancreatic cancer
- Tumor microenvironment
- Protease-activated magnetic nanosensor (PAC-MANN) assay
- Clinical diagnosis
Biography
Dr. Jared Fischer, Ph.D., is an Assistant Professor of Molecular and Medical Genetics at Oregon Health & Science University, where his research focuses on understanding tumor biology and developing innovative methods for early cancer detection and diagnosis. He studies tissues from unique mouse models to elucidate the phenotypic progression involved in tumor formation, aiming to translate insights into better diagnostic tools. Dr. Fischer earned his Ph.D. in molecular genetics from the University of Cincinnati and is actively involved in research projects such as the development of minimally invasive blood-based tests for detecting biomarkers associated with pancreatic cancer.
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Fischer, J.M. (2026, February 26). PAC-MANN assay: a breakthrough in non-invasive early detection of pancreatic cancer [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 19, 2026, from https://doi.org/10.69645/HIYL1310.Export Citation (RIS)
Publication History
- Published on February 26, 2026
Financial Disclosures
- Dr. Jared M. Fischer has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
PAC-MANN assay: a breakthrough in non-invasive early detection of pancreatic cancer
Published on February 26, 2026
10 min
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: A
promising new assay for
the early detection
of pancreatic cancer
was recently featured in a paper
published in Science
Translational Medicine.
Behind this publication is
the research group led by
Professor Jared Fischer at
Oregon Health and
Science University.
Professor Fischer has
kindly joined us today
to discuss this
groundbreaking discovery.
Professor Fischer, thank you
very much for your time.
Dr. Fischer: Thank
you for inviting me.
I'm very excited to talk about
this important breakthrough.
Interviewer: Can you start by
providing a bit of background
on pancreatic cancer
and the challenges
associated with its diagnosis?
Dr. Fischer: Pancreatic
cancer is one of
the most devastating diseases,
with only a 3% survival rate
when it is diagnosed
at a later stage.
But if we can find the
pancreatic cancer early,
at an earlier stage before it
has spread throughout the body,
then the survival
rate is nearly 50%.
It goes from 3% to 50%.
The biggest problem of
pancreatic cancer is that
there's no screening
method for it.
It's typically found
just accidentally from
an unrelated medical condition,
which then typically means
it's found at a later stage.
The early warning signs
for pancreatic cancer are
very vague, such as just
pain in the abdomen,
yellowing of the skin, fatigue,
recent onset diabetes is one,
rapid weight loss is another.
These things could mean
any number of things,
not just pancreatic cancer.
With no screening
method, we are stuck
just hoping that you can
accidentally find it.
That is why a lot of
different groups,
including our own,
have been trying to
develop a pancreatic
screening method
that we will get into
exactly how that works.
But this is why pancreatic
cancer is so deadly,